Tessellate Bio draws $8.4M in seed to try alternative synthe

With an initial €8 million (US$8.4 million) in seed funding in the bank, Tessellate Bio has emerged from stealth to tackle cancers that rely on the less well explored synthetic lethality mechanism of alternative lengthening of telomeres.

Related Keywords

, Tessellate Bio , Telomeres , Synthetic Lethality , Salt , Oncology , Fancm ,